Introduction
============

The most recent data indicate that lung cancer remains the type of cancer with the highest prevalence among men and women and is also one of the most common causes of cancer-related mortality ([@b1-ijo-53-04-1557]). Approximately 1.82 million cases of lung cancer are newly diagnosed globally each year, and approximately 1.37 million individuals succumb to the disease ([@b2-ijo-53-04-1557]--[@b4-ijo-53-04-1557]). Based on the histological classification, lung cancers are divided into 2 types: Non-small cancer lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for 85% of all lung cancer cases ([@b5-ijo-53-04-1557]). NSCLS includes a number of histological subtypes, including lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and large cell carcinoma (LCC). LUAD is one of the main subtypes of NSCLC ([@b6-ijo-53-04-1557]). Despite in-depth studies and significant progress being made in lung cancer treatment in recent decades ([@b7-ijo-53-04-1557]--[@b10-ijo-53-04-1557]), comprehensive clinical evaluation and in-depth molecular mechanistic studies are still required. Therefore, further investigations of the pathological mechanisms of NSCLC are warranted. Thus, the screening of novel functional genes and targets in NSCLC may provide basic data and a preliminary theoretic basis for further studies on the pathogenesis of NSCLC.

The homeobox (*HOX*) gene family is composed of 39 genes. These genes play critical roles in normal embryonic development by encoding transcription factors. The *HOX* gene family is divided into 4 groups: *HOXA*, *HOXB*, *HOXC* and *HOXD*. These genes localize to different chromosomal regions. The human *HOXA* gene cluster localizes to chromosome 7. There are 12 genes, including *HOXA1* to *HOXA11* and *HOXA13* ([@b11-ijo-53-04-1557]--[@b13-ijo-53-04-1557]). The *HOXA* gene cluster plays important roles in colorectal cancer, leukaemia, pancreatic cancer, oral squamous cell carcinoma and lung cancer ([@b14-ijo-53-04-1557]--[@b18-ijo-53-04-1557]). For *HOXA3*, only one study suggests that it nat be used as a biomarker of LUAD. This study was conducted by Daugaard *et al* ([@b19-ijo-53-04-1557]). These researchers used a DNA methylation microarray to compare the genome-wide methylation patterns between tumour and tumour-adjacent lung tissues from 4 patients with LUAD and identified 74 differential methylation regions (DMRs). Through methylation sensitive-high resolution melting (MS-HRM) analyses, 18 DMRs were selected for validation in 52 LUAD tissues and 32 cancer-adjacent lung tissues. Finally, this study confirmed and validated 15 DMRs, including *HOXA3*, that could be used as biomarkers of LUAD ([@b19-ijo-53-04-1557]). However, studies on the clinical significance and regulatory mechanisms of *HOXA3* expression in NSCLC are still lacking. Therefore, further studies are urgently required to examine *HOXA3* expression in NSCLC and to investigate the potential regulatory mechanisms in order to provide new insight into the pathogenic mechanisms of NSCLC.

In this study, we used reverse transcription-quantitative PCR (RT-qPCR) to detect *HOXA3* expression in NSCLC and normal lung tissues. *HOXA3* expression in NSCLC was validated using the Gene Expression Profiling Interactive Analysis (GEPIA) database. In addition, informatics analysis methods, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction (PPI), were performed to investigate the potential molecular mechanisms of action of *HOXA3*. Furthermore, the potential target microRNAs (miRNAs or miRs) of *HOXA3* were predicted using miRWalk2.0. The expression levels of miRNAs were validated using the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TGCA) databases. The study design is presented in [Fig. 1](#f1-ijo-53-04-1557){ref-type="fig"}.

Materials and methods
=====================

Clinical samples
----------------

A total of 55 tissues of cases of clinical NSCLC and cancer-adjacent lung tissues were collected (from January, 2012 to February, 2014) at the Department of Pathology of The First Affiliated Hospital of Guangxi Medical University (Nanning, China). Among these 55 patients, 32 cases were diagnosed with LUAD, and 23 cases were diagnosed with LUSC. There were 41 men and 14 women. Patients were 23--90 years of age with a mean age of 56.9 years. Among these 55 cases, tumours in 39 cases were larger than 3 cm. [Table I](#tI-ijo-53-04-1557){ref-type="table"} summarizes the detailed clinicopathological data of all the patients. Samples were fixed in formalin and embedded in paraffin. This research programme was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. All participants signed informed consent forms. All samples were diagnosed by 2 pathologists (G.C. and D.-M.W.) independently using the double-blind method.

Detection of HOXA3 expression by RT-qPCR
----------------------------------------

*HOXA3* expression in NSCLC samples was detected by RT-qPCR which was performed as previously described ([@b20-ijo-53-04-1557]--[@b22-ijo-53-04-1557]). Total RNA was extracted from the tumour and cancer-adjacent normal tissues using the RNeasy reagent (Qiagen, Shanghai, China). The RNA concentration was measured using NanoDrop2000 (Thermo Fisher Scientific, Wilmington, DE, USA). Total RNA was reverse transcribed (10 µl reaction system) using a reverse transcription kit (ABI, Life Technologies, Carlsbad, CA, USA) to obtain cDNA for RT-qPCR. SYBR-Green (Shanghai GeneCore BioTechnologies Co., Ltd., Shanghai, China) was used to perform RT-qPCR and the distinctiveness of the PCR product was differentiated based on melting curve ([@b23-ijo-53-04-1557]--[@b26-ijo-53-04-1557]). RT-qPCR was carried out using the following conditions: preheating for 10 min at temprature 95°C; and then repeating 40 cycles in temperature 95°C for 15 sec and 60 sec at 60°C. The primer sequences of *HOXA3* were as follows: Upstream, TCATTTAAGAGCGCCTGGACA and downstream primer, GAGCTGTCGTAGTAGGTCGC. Using *GAPDH* as an internal reference gene and the primer sequence were as follows: Upstream, 5′-TGGTCCCTGCTCCTCTAAC-3′, downstream primer, 5′-GGCTCAATGGCGTACTCTC-3′. The relative expression level of *HOXA3* in this study was calculated using the 2^−ΔΔCq^ ([@b27-ijo-53-04-1557]) formula ([@b28-ijo-53-04-1557], [@b29-ijo-53-04-1557]).

Retrieval of TCGA data
----------------------

GEPIA (<http://gepia.cancer-pku.cn/>) is a visualization website based on TCGA data and contains differential gene expression between cancer and non-cancer, and analysis of the association between gene expression and overall survival (OS) or disease-free survival (DFS) and clinical stages (Stage). Survival analyses were performed using the log-rank test (also known as Mantel-Cox test) for hypothesis tests and calculation of the hazard ratio (HR) and 95% confidence interval (95% CI). Keywords, such as \'*HOXA3*\', \'LUAD\' and \'LUSC\', were searched in GEPIA to retrieve data of the differential expression of *HOXA3* in NSCLS, LUAD, LUSC and normal lung tissues, as well as information regarding the association between *HOXA3* and clinical stages and prognostic survival.

The keywords \'lung\' and \'*HOXA3*\' were searched in the cBioPortal (<http://www.cbioportal.org/>) website to retrieve genetic alteration data of *HOXA3* in LUAD and LUSC. Data were obtained from microarray detection and RNA sequencing. In addition, DNA methylation data in LUAD and LUSC were downloaded from the Cancer Genome Atlas (TCGA: <https://cancergenome.nih.gov/abouttcga/overview>) database. *HOXA3* methylation data in LUAD and LUSC were screened.

HOXA3 co-expression genes
-------------------------

To investigate the intrinsic mechanisms of *HOXA3* expression in NSCLC tissues, we acquired *HOXA3*-associated co-expression genes from the MEM (<http://biit.cs.ut.ee/mem>) and cBioPortal databases. In MEM, when the score/P-value was smaller, the association between that gene and *HOXA3* was more significant. The results of 2 gene probes were extracted from MEM based on a P-value \<0.0001, and the results were used for intersection. On the other hand, Pearson\'s correlation analysis was performed in cBioPortal to calculate the correlation between co-expression genes and *HOXA3*. When the absolute value of the Pearson\'s correlation coefficient was larger, the correlation was stronger. This study selected genes with an absolute value of the Pearsons\' correlation coefficient \>0.3 in NSCLC, LUAD and LUSC. Finally, the intersection results between MEM and cBioPortal were obtained and used for further analyses. The overlapping genes were confirmed using a Venn diagram (<http://bioinformatics.psb.ugent.be/webtools/Venn/>).

Bioinformatics analyses
-----------------------

In this study, we used bioinformatics analyses to preliminarily investigate the molecular mechanisms of action of *HOXA3* in NSCLC. The final overlapping genes in MEM and cBioPortal were used for GO and KEGG analyses in David v6.7 (<http://david.abcc.ncifcrf.gov/>) to elucidate the enrichment of genes in biological processes and signalling pathways. PPI analyses were performed in STRING v10.5 (<https://string-db.org/cgi/input.pl?input_page_show_search=on&UserId=HJJhhNv8hYyf&sessionId=Ce1Dx9pYDluc>) to validate the protein interaction association to hypothesize the pathways through which *HOXA3* carries out its functions in NSCLC. The construction of the functional network was performed using Cytoscape 3.5.0 software and ClueGO plugin.

Prediction and preliminary validation of target miRNAs of HOXA3
---------------------------------------------------------------

The prediction of target miRNAs of *HOXA3* was performed in miRWalk2.0 (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>). miRWalk2.0 contains 12 on-line target gene prediction tools: Pictar2, miRWalk, miRMap, DIANA microT v4, PITA, miRanda, RNA22, mirBridge, miRDB, RNAhybrid, miRNAMap and TargetScan. miRNAs that were present in \>8 software results were used as candidate miRNAs for further analyses.

The microarray results of differentially expressed miRNAs in lung cancer were searched in the GEO database and downloaded. The following search formula was employed: (lung OR pulmonary OR respiratory OR bronchi OR bronchioles OR alveoli OR pneumocytes OR \'air way\') AND (cancer OR carcinoma OR tumor OR neoplas\* OR malignan\* OR adenocarcinoma) AND (microRNA OR miRNA OR \'micro RNA\' OR \'small temporal RNA\' OR \'noncoding RNA\' OR ncRNA OR \'small RNA\'). We included microarray data containing expression data of miRNAs in lung cancer tissues and normal lung tissues and a sample number \>3 into this study. Microarray data that did not conform to this condition were excluded. In addition, miRNA expression data for the LUAD, LUSC and normal lung tissues were extracted from the TCGA database. The mean value ± standard deviation (means ± SD) of the expression of potential target miRNAs in tumour and non-tumour tissues in each microarray was calculated. The random effects model was used to calculate the standardized mean difference (SMD) in STATA 2.0 software to evaluate the expression trend of miRNAs in NSCLC and plot the forest plot. In addition, analyses using the sROC method were performed to further validate the expression trend of miRNAs in NSCLC.

Statistical analyses
--------------------

Statistical analyses of the experimental data were performed using SPSS 22.0 software (IBM, New York, NY, USA). The *HOXA3* expression levels detected by RT-qPCR were expressed as the means ± SD and the Mann-Whitney test was used to determine significance. The normal distribution was determined using the single-sample K-S test. The comparison of the association between the *HOXA3* expression level and the patient clinicopathological characteristics, and the comparison of mean values of 2 factors were performed using the independent sample t-test when variances were homogeneous. When variances were not homogeneous, rank sum statistical analysis was performed. The comparison of the mean values of multiple factors was performed using one-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test, with a default P-value of 0.05. The differences in *HOXA3* expression levels between the NSCLC and normal lung tissues were further validated using the calculation of the area under the ROC curve. The Kaplan-Meier curve method was performed to analyse the association between the *HOXA3* expression level and NSCLC patient survival. Pearson\'s correlation analysis was used to calculate the correlation between two genes. GraphPad Prism was used to generate the scatter plot. Meta-analysis of target miRNAs in NSCLC and normal lung tissues was performed using the STATA 12.0 software. P\<0.05 in all analytic results indicated that the differences exhibited statistical significance.

Results
=======

HOXA3 expression in NSCLC
-------------------------

For NSCLC, the *HOXA3* expression level in the cancer tissues was 0.11±0.14 and the fold change (FC), 0.60 (FC is the fold change of *HOXA3* expression in tumour and non-tumour adjacent tissue). Compared with the normal lung tissues (0.19±0.20, P=0.006), *HOXA3* expression was significantly decreased (P=0.006; [Fig. 2A](#f2-ijo-53-04-1557){ref-type="fig"}). The median of the *HOXA3* level was 0.06 and the FC, 0.5 (control, 0.12; P=0.008). The area under the ROC curve (AUC) of low *HOXA3* expression in NSCLC was 0.65 (95% CI: 0.54, 0.76; P=0.008, [Fig. 2B](#f2-ijo-53-04-1557){ref-type="fig"}). Therefore, a low *HOXA3* expression may have some value in the occurrence of NSCLC. A low *HOXA3* expression was not significantly associated with the clinicopathological characteristics ([Table I](#tI-ijo-53-04-1557){ref-type="table"}). In addition, in LUAD, the mean expression level of *HOXA3* was 0.13±0.17 and the FC, 0.55. *HOXA3* expression was significantly decreased in LUAD compared with the cancer-adjacent normal tissues (0.24±0.24, P=0.023) ([Fig. 2C](#f2-ijo-53-04-1557){ref-type="fig"} and [Table I](#tI-ijo-53-04-1557){ref-type="table"}). The median of the *HOXA3* level was 0.08 and the FC, 0.62 (control, 0.13; P=0.034). The AUC of downregulated *HOXA3* expression in LUAD was 0.66 (95% CI: 0.52, 0.80; P=0.035) (data not shown). Further analyses revealed that the *HOXA3* level in smokers (0.06±0.04) was reduced compared with that in non-smokers (0.186±0.20, P=0.025) ([Fig. 2D](#f2-ijo-53-04-1557){ref-type="fig"} and [Table I](#tI-ijo-53-04-1557){ref-type="table"}). The AUC of downregulated *HOXA3* in the smoking group was 0.70 (95% CI: 0.51, 0.89; P=0.069) (data not shown). The combination of the above-mentioned data analyses demonstrated that the downregulation of *HOXA3* expression in LUAD was significant. In addition, *HOXA3* expression in LUAD may be associated with smoking, but did not exhibit a significant association with other clinicopathological characteristics. The analyses of the LUSC group alone revealed that *HOXA3* expression differed significantly between the cancer tissues and non-cancer tissues (cancer, 0.09±0.08 vs. control, 0.12±0.09, P=0.034, FC, 0.72) ([Fig. 2E](#f2-ijo-53-04-1557){ref-type="fig"} and [Table I](#tI-ijo-53-04-1557){ref-type="table"}). The median of the *HOXA3* level was 0.06 and the FC, 0.5 (control, 0.12; P=0.113). The AUC of the low *HOXA3* level in the LUSC group was 0.64 (95% CI: 0.47, 0.81; P=0.113) (data not shown). The low expression of HOX3A in LUSC was not significantly associated with disease progression.

In addition, the GEPIA data revealed that *HOXA3* expression in LUAD (483 cases) was also significantly decreased compared with the normal lung tissues (347 cases) and exhibited a low expression trend in LUSC (LUSC, 486 cases; normal, 338 cases) ([Fig. 3A](#f3-ijo-53-04-1557){ref-type="fig"}). These results were consistent with the results of RT-qPCR. However, the association between the *HOXA3* expression level and the pathological stage did not exhibit an obvious pattern ([Fig. 3B](#f3-ijo-53-04-1557){ref-type="fig"}). We also acquired information regarding the association between the *HOXA3* expression level and the survival of patients with NSCLC, LUAD and LUSC. Patients with NSCLC with a low *HOXA3* expression exhibited a better OS \[HR (high), 1.3; P=0.0035\] ([Fig. 4A](#f4-ijo-53-04-1557){ref-type="fig"}, panel a). Thus, a low *HOXA3* expression may be a protective factor of OS in patients with NSCLC. However, further analysis demonstrated that *HOXA3* was not significantly associated with the DFS of patients with NSCLC ([Fig. 4A](#f4-ijo-53-04-1557){ref-type="fig"}, panel d). The analyses of OS in the LUAD group alone demonstrated that patients with a high *HOXA3* expression exhibited an HR of 1.4 (P=0.042) ([Fig. 4A](#f4-ijo-53-04-1557){ref-type="fig"}, panel b), suggesting that a high *HOXA3* level may be a risk factor for the prognosis of LUAD. However, the *HOXA3* expression levels did not exhibit obvious predictive values as regards the DFS of patients with LUAD ([Fig. 4A](#f4-ijo-53-04-1557){ref-type="fig"}, panel e). In addition, the association between *HOXA3* and the prognosis of patients LUSC was not statistically significant ([Fig. 4A](#f4-ijo-53-04-1557){ref-type="fig"}, panels c and f), and this may require further investigation.

Furthermore, based on the microarray and RNA sequencing technologies, the sequencing results of 520 patients with LUAD revealed that the genetic alteration rates of *HOXA3* were 5% (24/520) and 11% (59/520). In addition, the sequencing results of 504 patients LUSC suggested that the genetic alteration rates of *HOXA3* were 5% (25/504), 7% (35/504) and 4% (18/504). Although the genetic alternation rates obtained using different methods differed, the final results all confirmed that *HOXA3* harboured genetic alterations in the LUAD and LUSC populations ([Fig. 4B](#f4-ijo-53-04-1557){ref-type="fig"}).

*On the other hand, the methylation level of HOXA3 in the NSCLC tissues was 0.57±0.21 (FC, 1.32; P\<0.001*; [Fig. 5A](#f5-ijo-53-04-1557){ref-type="fig"}), with an AUC value of 0.72 (95% CI: 0.68, 0.76; P\<0.001, [Fig. 5D](#f5-ijo-53-04-1557){ref-type="fig"}). The methylation level in the LUAD tissues was 0.56±0.20 (FC, 1.27; P\<0.001; [Fig. 5B](#f5-ijo-53-04-1557){ref-type="fig"}), and an AUC value of 0.70 (95% CI: 0.64, 0.76; P\<0.001, [Fig. 5E](#f5-ijo-53-04-1557){ref-type="fig"}). The methylation level in the LUSC tissues was 0.58±0.21 (FC, 1.38; P\<0.001; [Fig. 5C](#f5-ijo-53-04-1557){ref-type="fig"}), and the AUC value was 0.74 (95% CI: 0.68, 0.79; P\<0.001, [Fig. 5F](#f5-ijo-53-04-1557){ref-type="fig"}) ([Table II](#tII-ijo-53-04-1557){ref-type="table"}). Compared with the normal tissues (NSCLC, 0.43±0.11; LUAD, 0.44±0.11; LUSC, 0.42±0.11), these levels were all significantly upregulated.

HOXA3 co-expression genes
-------------------------

Based on MEM, 11,488 and 4,730 *HOXA3* co-expression mRNA genes detected by 2 independent gene probes were obtained. The intersection between the results of 2 gene probes was collected, and a total of 1,709 more convincing co-expression mRNA genes were extracted. The data from cBioPortal revealed 3,600 and 2,676 co-expression mRNA genes in the NSCLC group and the LUAD group, respectively. Finally, the search results of the NSCLC group and the LUAD group in MEM and cBioPortal were processed using the crossing method (data not shown). In total, 293 and 213 genes were obtained, respectively, for further analysis.

Bioinformatics analyses
-----------------------

GO and KEGG analyses were performed on 293 and 213 genes in DAVID, and PPI network analyses were performed in STRING. The results from GO analysis revealed that genes in the NSCLC group mainly participated in biological processes, such as the regulation of cell migration; the regulation of apoptosis; and the regulation of programmed cell death; cellular components, such as insoluble fraction, membrane fraction, and extracellular matrix; and molecular functions, such as sequence-specific DNA binding, enzyme activator activity, and phosphatidylinositol-3,4,5-tri-sphosphate binding ([Figs. 6](#f6-ijo-53-04-1557){ref-type="fig"} and [8A--C](#f8-ijo-53-04-1557){ref-type="fig"}, and [Table III](#tIII-ijo-53-04-1557){ref-type="table"}). The results of KEGG pathway analyses suggested that *HOXA3* may be involved in the functional regulation of 22 signalling pathways in the NSCLC group. The most important pathways were focal adhesion, pathways in cancer, and the TGF-β signalling pathway ([Figs. 7](#f7-ijo-53-04-1557){ref-type="fig"} and [8D](#f8-ijo-53-04-1557){ref-type="fig"}, and [Table IV](#tIV-ijo-53-04-1557){ref-type="table"}). In addition, genes in the LUAD group mainly participated in biological processes, such as the regulation of cell migration, regulation of apoptosis and the regulation of programmed cell death. Significant enrichment also occurred in cellular components and molecular functions; for example, insoluble fraction and membrane fraction in cellular components and sequence-specific DNA binding and enzyme activator activity in molecular functions ([Figs. 9](#f9-ijo-53-04-1557){ref-type="fig"} and [11A--C](#f11-ijo-53-04-1557){ref-type="fig"}, and [Table V](#tV-ijo-53-04-1557){ref-type="table"}). The analytical results in the LUAD group suggested that *HOXA3* may be involved in the biological regulation of 15 signalling pathways. Of these pathways, the most significant pathways were focal adhesion and ECM-receptor interaction ([Figs. 10](#f10-ijo-53-04-1557){ref-type="fig"} and [11D](#f11-ijo-53-04-1557){ref-type="fig"}, and [Table VI](#tVI-ijo-53-04-1557){ref-type="table"}). In PPI analyses, 278 interaction nodes were obtained in the NSCLC group ([Fig. 12A](#f12-ijo-53-04-1557){ref-type="fig"}). The genes with the top 10 overall scores are presented in [Table VII](#tVII-ijo-53-04-1557){ref-type="table"}. The results of interaction network analyses demonstrated that *MAPK1*, *EGFR*, *DCN* and *CFTR* represented key genes in these networks. In addition, genes enriched in \'Focal adhesion\' were used for PPI analyses, and a total of 13 interaction nodes were obtained ([Fig. 12B](#f12-ijo-53-04-1557){ref-type="fig"}). The genes with the top 10 overall score are presented in [Table VIII](#tVIII-ijo-53-04-1557){ref-type="table"}. The results suggested that *MAPK1*, *EGFR*, *TNC* and *COL1A1* were key genes in this pathway. PPI analyses were also performed on genes in the LUAD group, and the results generated 129 protein interaction nodes ([Fig. 13](#f13-ijo-53-04-1557){ref-type="fig"}). The nodes with the top 10 overall scores are presented in [Table IX](#tIX-ijo-53-04-1557){ref-type="table"}. The protein interaction network suggested that *MAPK1*, *EGFR*, *CFTR* and *GLI3* were key nodes in these interaction networks. Genes in the LUAD group that were enriched in \'Focal adhesion\' were used for PPI analyses, and 14 protein interaction network nodes were also obtained. The result was the same as that for the NSCLC group. *MAPK1*, *EGFR*, *TNC* and *COLIA1* were key genes in these pathways (refer to [Fig. 12B](#f12-ijo-53-04-1557){ref-type="fig"} and [Table X](#tX-ijo-53-04-1557){ref-type="table"}). Analytic results revealed that genes in the NSCLC and LUAD groups all participated in the regulation of the \'Focal adhesion\' pathway. *MAPK1* and *EGFR* played key roles in NSCLC and LUAD, whereas *MAPK1*, *EGFR*, *CFTR* and *GLI3* represented key genes in the \'Focal adhesion\' pathway. Therefore, these 4 genes were analysed further. Based on TCGA data, the results of Pearson\'s correlation analysis revealed that the 4 genes, *EGFR*, *MAPK1*, *COL1A1* and *TNC*, all exhibited a potential positive correlation with *HOXA3* expression in NSCLC ([Fig. 14](#f14-ijo-53-04-1557){ref-type="fig"}). In the LUAD group, only *COL1A1* and *TNC* exhibited a possible positive correlation with *HOXA3* ([Fig. 15C and D](#f15-ijo-53-04-1557){ref-type="fig"}).

Prediction and preliminary validation of HOXA3 target miRNAs
------------------------------------------------------------

*HOXA3* had 3 target miRNAs that passed the target prediction. Based on GEO microarray search and TCGA database, the random effects model was used for meta-analyses of the expression of these 3 miRNAs in NSCLC tissues. The results revealed that the expression of hsa-miR-372-3p was significantly increased in the NSCLC and LUAD tissues, but only exhibited an increasing trend in the LUSC tissues (NSCLC P\<0.001, LUAD P=0.017, and LUSC P=0.243) ([Fig. 16A](#f16-ijo-53-04-1557){ref-type="fig"}). In addition, hsa-miR-372-3p and HOX3A had 1 fragment of complementary sequences of ′3′CGUGAA5′-3′ GCACUU-5″ ([Fig. 16B](#f16-ijo-53-04-1557){ref-type="fig"}). Furthermore, the sensitivity and specificity of miR-372-3p expression in NSCLC were examined using the sROC method. The results suggested that the optimal sensitivity and specificity of a high miR-372-3p expression in the NSCLC group were SENS, 0.71 (0.57, 0.83) and SPES, 0.65 (0.52, 0.76), respectively, and the AUC was 0.73 (95% CI: 0.69, 0.77). The optimal sensitivity and specificity of the LUAD group were SENS, 0.65 (0.5, 0.77) and SPES, 0.66 (0.43, 0.83), respectively, and the AUC was 0.69 (95% CI: 0.65, 0.73) ([Fig. 16C and D](#f16-ijo-53-04-1557){ref-type="fig"}).

Discussion
==========

This study used qPCR detection and TCGA RNA-seq data to confirm that *HOXA3* expression was significantly down-regulated in LUAD tissues. The downregulation of *HOXA3* may be closely associated with a more favourable prognosis of LUAD. In addition, the TCGA data indicated that *HOXA3* harboured genetic alterations in 11--55% of LUAD tissues, and the methylation level of *HOXA3* in LUAD tissues was significantly upregulated. Combined with the TCGA data, the upregulation of the *HOXA3* level in LUSC was not significant. Therefore, we paid more attention to the clinical significance and molecular mechanisms of action of *HOXA3* in LUAD. Through the collection of co-expression genes and GO and KEGG analyses, the preliminary results revealed that *HOXA3* may play important roles in LUAD through the regulation of focal adhesion and ECM-receptor interaction signalling pathways. Furthermore, through the prediction of *HOXA3* target miRNAs and meta-analyses of target miRNA expression based on the GEO microarray and TCGA data, the results confirmed that the expression of miR-372-3p that had complementary sequences with *HOXA3* was significantly increased in LUAD tissues.

There have been some studies of the association between the *HOXA3* level and tumours. For example, Zhang *et al* ([@b30-ijo-53-04-1557]) demonstrated that *HOXA3* exhibited a high expression in both colorectal cancer tissues and cell lines. Shen *et al* ([@b31-ijo-53-04-1557]) assessed the association between HOX family genes and nasopharyngeal carcinoma and demonstrated that *HOXA3* expression was also upregulated. Kuasne *et al* ([@b32-ijo-53-04-1557]) suggested that *HOXA3* exhibited a low expression in penile carcinoma. At least to the best of our knowledge, only 1 methylation-related study on the association between *HOXA3* and LUAD has been reported ([@b19-ijo-53-04-1557]). This study, to the best of our knowledge, was the first to detect *HOXA3* mRNA expression in LUAD. Combined with qPCR detection and TCGA data, we confirmed that *HOXA3* expression was downregulated in LUAD tissues, and a low *HOXA3* expression may play a important role in LUAD.

The investigation of the association between *HOXA3* and tumour progression has demonstrated that a high *HOXA3* expression is associated with low survival rates in colon cancer ([@b33-ijo-53-04-1557]). In penile carcinoma, a low *HOXA3* expression was found to be associated with a poor prognosis ([@b32-ijo-53-04-1557]). However, the association between *HOXA3* and the progression of nasopharyngeal carcinoma has not been studied in depth ([@b31-ijo-53-04-1557]). Our analyses of *HOXA3* expression in all pathological stages of LUAD did not exhibit an obvious pattern. The survival analyses demonstrated that patients LUAD with a low *HOXA3* expression had a better OS. Therefore, we hypothesized that the downregulation of *HOXA3* expression may be an independent protective factor in LUAD.

Furthermore, based on the microarray and RNA Seq data in TCGA, we preliminarily revealed that *HOXA3* harboured a certain level of genetic alterations in LUAD tumour tissues. Thus, we would like to acquire more information for further validation. However, relevant studies are currently lacking, and literature reports are not available, at least to the best of our knowledge. As regards gene methylation, Kuasne *et al* performed genome-wide methylation studies on penile carcinoma and confirmed that 8 genes, including *HOXA3*, exhibited high methylation levels ([@b32-ijo-53-04-1557]). In a validation study of epigenetic biomarkers in LUAD, Daugaard *et al* ([@b19-ijo-53-04-1557]) performed genome-wide methylation microarray sequencing on 4 cases of LUAD tissues and normal cancer-adjacent lung tissues to screen differentially methylated genes in LUAD. They selected the 18 most significantly differentially methylated genes, including *HOXA3*, for validation in 52 samples. The methylation level of *HOXA3* significantly increased ([@b19-ijo-53-04-1557]). This study acquired *HOXA3* methylation data from the TCGA database to perform analyses. The results suggested that the *HOXA3* methylation level was significantly increased in LUAD tissues. This finding was consistent with the results in literature reports. Combined with *HOXA3* mRNA expression levels in LUAD, the function of *HOXA3* in LUAD may be associated with the increase in the methylation level. In addition, the study by Daugaard also demonstrated that the increase of *HOXA3* methylation was even more evident in patients with tumour metastasis; however, its association with the prognostic survival rates in LUAD patients has not been elucidated ([@b19-ijo-53-04-1557]). Despite the results of this study, sufficient evidence is not yet available to confirm the association between the methylation level of *HOXA3* and LUAD progression. Thus, further studies are required for confirmation. As regards studies on the association between DNA methylation and mRNA expression, Kuasne *et al* ([@b32-ijo-53-04-1557]) performed qPCR detection to demonstrate that genes with high methylation levels exhibited a low expression in penile carcinoma. These results confirmed that the methylation level and mRNA expression exhibited a negative correlation ([@b32-ijo-53-04-1557]). Zhang *et al* performed cell experiments to confirm that a group of genes (*S100P*, *GDA*, *WISP2*, *LOXL1*, *TIMP4*, *ICAM1*, *CLMP*, *HSP8*, *GAS1* and *BMP2*) exhibited a downregulated mRNA expression through high methylation levels to induce drug resistance in NSCLC ([@b34-ijo-53-04-1557]). Jin *et al* demonstrated that 19 genes mediated the downregulation of mRNA expression through the increase in upstream methylation levels in LUAD ([@b35-ijo-53-04-1557]). This study confirmed the low expression of *HOXA3* in LUAD and the increase in the methylation level. Based on these findings, we hypothesized that *HOXA3* methylation has a negative regulatory association with mRNA expression and plays critical roles in tumour development and progression.

To investigate the underlying molecular mechanisms, GO and KEGG analyses were performed to compare the enrichment of *HOXA3* co-expression genes between the NSCLC group and the LUAD group. The results demonstrated that the enrichment conditions in biological processes, cellular components, and molecular functions were basically the same. Some differences in the KEGG signalling pathways were noted. The LUAD group was more concentrated on the focal adhesion and ECM-receptor interaction pathways. *HOXA3* may carry out its regulatory functions in LUAD through participation in these 2 signalling pathways. The focal adhesion signalling pathway is a critical pathway to activate focal adhesion kinase (FAK). Kinases activated by this pathway mainly mediate a variety of cellular metabolic processes, including cell metastasis, growth factor signal transduction, cell survival, cell cycle progression, and cell movement, and are closely associated with the development of malignant tumours ([@b36-ijo-53-04-1557]--[@b38-ijo-53-04-1557]). Currently, there are literature reports on using FAK as a novel potential biological target to investigate targeted therapy of NSCLC ([@b39-ijo-53-04-1557],[@b40-ijo-53-04-1557]). The ECM-receptor interaction signalling pathway mediates the expression of enriched genes and regulates functions of these genes to promote tumour cell proliferation and migration and participate in tumour metastasis and infiltration ([@b41-ijo-53-04-1557],[@b42-ijo-53-04-1557]). In NSCLC unrelated to smoking, the ECM-receptor interaction signalling pathway plays a critical role ([@b43-ijo-53-04-1557]). The above-mentioned 2 signalling pathways significantly influence the development and progression of human malignant tumours and act as the bridge between abnormal gene expression and malignant tumour development.

Therefore, in this study, we performed PPI analyses on genes enriched in the focal adhesion and ECM-receptor interaction signalling pathways and demonstrated that *MAPK1*, *EGFR*, *TNC* and *COL1A1* served as core genes in these 2 pathways. In addition, based on the TCGA data, Pearson\'s correlation analyses demonstrated that only *TNC* and *COL1A1* exhibited significantly positive correlations with *HOXA3* expression in LUAD. One relevant study detected 72 cases of NSCLC tissues and normal lung tissues ([@b44-ijo-53-04-1557]). *TNC* expression was upregulated in NSCLC and was closely associated with TNM stage, lymph node metastasis and tumour pleural invasion. Other studies have also demonstrated that *TNC* upregulation is associated with a poor prognosis in LUAD ([@b45-ijo-53-04-1557],[@b46-ijo-53-04-1557]). The study by Oleksiewicz *et al* ([@b47-ijo-53-04-1557]) on 156 cases of NSCLC and normal lung tissues revealed that *COL1A1* was significantly overexpressed in tumour tissues. That study also performed cell experiments to confirm that *COL1A1* was closely associated with hypoxia responses in NSCLC ([@b47-ijo-53-04-1557]). Combined with bioinformatics analysis results, *HOXA3* may collaborate with co-expression genes, such as *TNC* and *COL1A1*, to regulate focal adhesion and ECM-receptor interaction signalling pathways, thus carrying out is functions in LUAD. However, more functional studies are required for further validation.

In this study, we also performed meta-analyses to confirm that the expression of the predicted miR-372-3p was upregulated in LUAD. Complementary sequences were noted between miR-372-3p and *HOXA3*. Combined with qPCR detection, *HOXA3* and miR-372-3p expression exhibited a negative correlation trend in LUAD. The results of a literature search demonstrated that miR-372-3p was highly expressed in both testicular cancer and LUSC. miR-372-3p promotes cell growth and migration in LUSC through the downregulation of the target gene *FGF9* ([@b48-ijo-53-04-1557],[@b49-ijo-53-04-1557]). Therefore, based on results of this study and those of studies in the literature, we hypothesized that the downregulation of *HOXA3* expression in LUAD tissues may be associated with the increase in miR-372-3p expression and *HOXA3* may carry out its function through the targeted upregulation of miR-372-3p. However, this hypothesis needs to be validated using various experiments.

In conclusion, combined with the RT-qPCR detection results and data from the TCGA and GEO databases, we confirmed that *HOXA3* expression was downregulated in LUAD tissues and exhibited a certain level of genetic alteration. The functions of downregulated *HOXA3* in tumour progression and a poor prognosis of patients with LUAD may be associated with increases in the methylation level. Furthermore, *HOXA3* may collaborate with co-expression genes, such as *TNC* and *COL1A1*, to regulate the focal adhesion and ECM-receptor interaction signalling pathways together or upregulate miR-372-3p to promote its carcinogenesis function. These study results provide true and reliable experimental data and rigorous molecular theories for further studies on the molecular mechanisms of *HOXA3* in LUAD.
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![(A) Scatter diagram of HOXA3 expression between NSCLC tissue and normal lung tissue detected by RT-qPCR. (B) ROC curve of HOXA3 expression in NSCLC tissue. (C and D) Scatter plots of HOXA3 level in LUAD detected by RT-qPCR. (C) Differences between cancer and non-cancer. (D) Differences between smoker and non-smoker in LUAD. (E) HOXA3 expression between LUSC tissue and normal lung tissue detected by RT-qPCR. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.](IJO-53-04-1557-g01){#f2-ijo-53-04-1557}

![(A) Boxplot of HOXA3 expression in LUAD tissues vs. non-cancerous tissues and LUSC tissues vs. non-cancerous tissues; ^\*^P\<0.05. (B) Pathological stage plot of HOXA3 levels in NSCLC. Panel a, NSCLC; panel b, LUAD; panel c, LUSC. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.](IJO-53-04-1557-g02){#f3-ijo-53-04-1557}

![(A) Survival curve of HOXA3 expression in NSCLC. Overall survival (OS: panel a, NSCLC; panel b, LUAD; panel c, LUSC) and disease-free survival (DFS: panel d, NSCLC; panel e, LUAD; panel f, LUSC). (B) The atlas of genetic alteration of HOXA3 mRNA in NSCLC. Panels a and b show HOXA3 mRNA expression z-scores by microarray and RNA Seq V2 RSEM in LUAD. Altered were 24 (5%) and 59 (11%) of 520 sequenced cases/patients (520 total) respectively; panels c, d and e show HOXA3 mRNA expression z-scores by U133 microarray only, microarray and RNA Seq V2 RSEM in LUSC. Altered were 18 (4%), 25 (5%) and 35 (7%) of 504 sequenced cases/patients (504 total). HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.](IJO-53-04-1557-g03){#f4-ijo-53-04-1557}

![Scatter plot of HOXA3 methylation levels between lung cancer tissues and normal lung tissues (A) NSCLC; (B) LUAD; (C) LUSC. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; ROC curve of HOXA3 methylation levels between lung cancer tissues and normal lung tissues (D) NSCLC; (E) LUAD; (F) LUSC.](IJO-53-04-1557-g04){#f5-ijo-53-04-1557}

![Network of gene ontology (GO) terms of HOXA3 co-expression genes in NSCLC constructed by cytoscape v3.5.0. (A-C) Show biological processes (BPs), cellular components (CCs) and molecular functions (MFs), respectively. In this network, only terms with statistically significant \[P\<0.01 (BP) or P\<0.05 (CC and MF)\] are displayed. Each node represents a GO term, and the node color indicates the P-value of a GO term. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer.](IJO-53-04-1557-g05){#f6-ijo-53-04-1557}

![(A) Network mappings were Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of HOXA3 co-expression genes in NSCLC. (B) The significant signalling pathways (P\<0.05) enriched in HOXA3 co-expression genes in NSCLC constructed by ClueGO plugin. The color of the circles represents the degree of enrichment of the pathway (P-value). HOXA3, homeobox A3; NSCLC, non-small cell lung cancer.](IJO-53-04-1557-g06){#f7-ijo-53-04-1557}

![Significantly enriched annotation of GO categories and KEGG pathways of HOXA3 co-expression genes in NSCLC. (A) Biological processes (BPs); (B) Cellular components (CCs); (C) Molecular factors (MFs); (D) KEGG pathways. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; HOXA3, homeobox A3; NSCLC, non-small cell lung cancer.](IJO-53-04-1557-g07){#f8-ijo-53-04-1557}

![The network of GO terms of HOXA3 co-expression genes in LUAD were constructed by cytoscape v3.5.0. (A-C) Biological processes (BPs), cellular components (CCs) and molecular functions (MFs), respectively. In this network, only terms with statistically significant (P\<0.05) are displayed. Each node represents a GO term, and the node color indicates the P-value of a GO term. GO, Gene Ontology; HOXA3, homeobox A3; LUAD, lung adenocarcinoma.](IJO-53-04-1557-g08){#f9-ijo-53-04-1557}

![(A) Network mappings of KEGG pathway anlaysis of HOXA3 co-expression genes in LUAD. (B) The significantly signalling pathways (P\<0.05) enriched HOXA3 co-expression genes in LUAD constructed by the ClueGO plugin. The color of circles represents the P-value of the signalling pathways. HOXA3, homeobox A3; KEGG, Kyoto Encyclopedia of Genes and Genomes; LUAD, lung adenocarcinoma.](IJO-53-04-1557-g09){#f10-ijo-53-04-1557}

![Significantly enriched annotation of GO categories and KEGG pathways of HOXA3 co-expression genes in LUAD. (A) Biological processes (BPs); (B) Cellular components (CCs); (C) Molecular factors (MFs); (D) KEGG pathway. HOXA3, homeobox A3; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; LUAD, lung adenocarcinoma.](IJO-53-04-1557-g10){#f11-ijo-53-04-1557}

![(A) PPI network analysis of genes co-expressed in HOXA3 in NSCLC and (B) the genes most implicated by the signalling pathways. PPI, protein-protein interaction; HOXA3, homeobox A3; NSCLC, non-small cell lung cancer.](IJO-53-04-1557-g11){#f12-ijo-53-04-1557}

![PPI network analysis of genes co-expressed in HOXA3 in LUAD. PPI, protein-protein interaction; HOXA3, homeobox A3; LUAD, lung adenocarcinoma.](IJO-53-04-1557-g12){#f13-ijo-53-04-1557}

![Correlation between the hub genes and the expression of HOXA3 in NSCLC. (A) MAPK1; (B) EGFR; (C) COL1A1; (D) TNC. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer.](IJO-53-04-1557-g13){#f14-ijo-53-04-1557}

![Correlation between the hub genes and the expression of HOXA3 in LUAD. (A) MAPK1; (B) EGFR; (C) COL1A1; (D) TNC. HOXA3, homeobox A3; LUAD, lung adenocarcinoma.](IJO-53-04-1557-g14){#f15-ijo-53-04-1557}

![(A) Forest profile of SMD of miR-372-3p expression between NSCLC and normal lung tissue. (B) The complementary sequences existing between miR-372-3p and HOXA3. (C and D) The combined sROC curve for miR-372-3P expression between NSCLC and normal lung tissue; (C) NSCLC and (D) LUAD. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma.](IJO-53-04-1557-g15){#f16-ijo-53-04-1557}

###### 

The association of between HOXA3 mRNA expression in NSCLC tissues and patient clinicopathological characteristics based on RT-qPCR detection.

  Clinicopathological characteristics   Case no.   HOXA3 expression   t-test of data                  
  ------------------------------------- ---------- ------------------ ---------------- ------ ------- -------
  Group                                                                                               
   Control                              55         0.19               0.20             1.00   2.86    0.006
   Cancer                               55         0.11               0.14             0.60           
  Pathological type                                                                                   
   Adenocarcinoma                       32         0.13               0.17             1.00   0.99    0.326
   Squamous cell carcinoma              23         0.09               0.08             0.70           
  LUAD                                                                                                
   Control                              32         0.23               0.24             1.00   −1.94   0.023
   Cancer                               32         0.13               0.17             0.55           
  LUAD                                                                                                
   Non-smoker                           18         0.18               0.20             1.00   2.42    0.025
   Smoker                               14         0.06               0.04             0.32           
  LUSC                                                                                                
   Control                              23         0.12               0.09             1.00   −1.32   0.034
   Cancer                               23         0.09               0.08             0.73           
  Sex                                                                                                 
   Male                                 41         0.12               0.15             1.00   0.35    0.732
   Female                               14         0.10               0.12             0.87           
  Age (years)                                                                                         
   \<60                                 35         0.12               0.15             1.00   0.25    0.801
   ≥60                                  20         0.11               0.12             0.91           
  Smoking                                                                                             
   No                                   30         0.14               0.17             1.00   1.91    0.064
   Yes                                  25         0.08               0.06             0.54           
  Size                                                                                                
   ≤3 cm                                16         0.12               0.12             1.00   0.09    0.931
   \>3 cm                               39         0.11               0.15             0.97           
  LNM                                                                                                 
   No                                   29         0.08               0.10             1.00   −1.66   0.103
   Yes                                  26         0.14               0.17             1.78           
  TNM                                                                                                 
   I--II                                29         0.09               0.11             1.00   −1.26   0.212
   III--IV                              26         0.14               0.17             1.54           
  Vascular invasion                                                                                   
   No                                   50         0.11               0.15             1.00   0.23    0.817
   Yes                                  5          0.10               0.03             0.85           
  Clinical grading                                                                                    
   I                                    5          0.09               0.08                            0.664
   II                                   40         0.12               0.16                            
   III                                  10         0.08               0.07                            

HOXA3, homeobox A3, an mRNA of homeobox genes of clusters A; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; SD, standard deviation; FC, fold change; LNM, lymph node metastasis. An independent sample t-test was adopted to test the data and single factor ANOVA was used to test the clinical grading data. The difference between the cancer and normal adjacent group was analyzed by a paired-samples t-test.

###### 

The association of between the HOXA3 mRNA methylation level in NSCLC tissues and normal adjacent tissues base on the TCGA data.

  Histological type   Case no.   HOXA3 methylation level   t-test of data                 
  ------------------- ---------- ------------------------- ---------------- ------ ------ ---------
  NSCLC                                                                                   
   Normal adjacent    86         0.43                      0.11             1.00   9.89   \<0.001
   Cancer             744        0.57                      0.21             1.32          
  LUAD                                                                                    
   Normal adjacent    43         0.44                      0.11             1.00   6.19   \<0.001
   Cancer             372        0.56                      0.20             1.27          
  LUSC                                                                                    
   Normal adjacent    43         0.42                      0.11             1.00   7.72   \<0.001
   Cancer             372        0.58                      0.21             1.38          

HOXA3, homeobox A3, an mRNA of homeobox genes of clusters A; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

###### 

The top ten most significant items of Gene Ontology (GO) terms of the co-expression genes of homeobox A3 (HOXA3) in non-small cell lung cancer.

  Category               Term                                                                                            Count   P-value    FDR
  ---------------------- ----------------------------------------------------------------------------------------------- ------- ---------- -------
  Biological processes                                                                                                                      
  GOTERM_BP_FAT          GO:0048706\~embryonic skeletal system development                                               8       3.41E-05   0.06
  GOTERM_BP_FAT          GO:0001501\~skeletal system development                                                         14      1.07E-04   0.18
  GOTERM_BP_FAT          GO:0045682\~regulation of epidermis development                                                 5       1.17E-04   0.19
  GOTERM_BP_FAT          GO:0030334\~regulation of cell migration                                                        10      1.80E-04   0.30
  GOTERM_BP_FAT          GO:0042981\~regulation of apoptosis                                                             23      1.97E-04   0.33
  GOTERM_BP_FAT          GO:0043067\~regulation of programmed cell death                                                 23      2.27E-04   0.38
  GOTERM_BP_FAT          GO:0010941\~regulation of cell death                                                            23      2.39E-04   0.40
  GOTERM_BP_FAT          GO:0048705\~skeletal system morphogenesis                                                       8       3.64E-04   0.60
  GOTERM_BP_FAT          GO:0040012\~regulation of locomotion                                                            10      4.64E-04   0.77
  GOTERM_BP_FAT          GO:0051270\~regulation of cell motion                                                           10      4.81E-04   0.80
  Cellular components                                                                                                                       
  GOTERM_CC_FAT          GO:0005626\~insoluble fraction                                                                  22      0.000184   0.24
  GOTERM_CC_FAT          GO:0005624\~membrane fraction                                                                   20      0.000837   1.07
  GOTERM_CC_FAT          GO:0031012\~extracellular matrix                                                                12      0.001071   1.37
  GOTERM_CC_FAT          GO:0044420\~extracellular matrix part                                                           7       0.001490   1.90
  GOTERM_CC_FAT          GO:0045177\~apical part of cell                                                                 8       0.002892   3.66
  GOTERM_CC_FAT          GO:0000267\~cell fraction                                                                       22      0.004675   5.86
  GOTERM_CC_FAT          GO:0042995\~cell projection                                                                     16      0.006747   8.35
  GOTERM_CC_FAT          GO:0005578\~proteinaceous extracellular matrix                                                  10      0.006859   8.48
  GOTERM_CC_FAT          GO:0016324\~apical plasma membrane                                                              6       0.013372   15.92
  GOTERM_CC_FAT          GO:0016323\~basolateral plasma membrane                                                         7       0.020688   23.61
  Molecular functional                                                                                                                      
  GOTERM_MF_FAT          GO:0043565\~sequence-specific DNA binding                                                       20      0.000041   0.06
  GOTERM_MF_FAT          GO:0008047\~enzyme activator activity                                                           11      0.004149   5.55
  GOTERM_MF_FAT          GO:0005547\~phosphatidylinositol-3,4,5-trisphosphate binding                                    3       0.004179   5.59
  GOTERM_MF_FAT          GO:0016641\~oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor   3       0.010187   13.11
  GOTERM_MF_FAT          GO:0030695\~GTPase regulator activity                                                           11      0.014540   18.21
  GOTERM_MF_FAT          GO:0016638\~oxidoreductase activity, acting on the CH-NH2 group of donors                       3       0.016640   20.58
  GOTERM_MF_FAT          GO:0060589\~nucleoside-triphosphatase regulator activity                                        11      0.016712   20.66
  GOTERM_MF_FAT          GO:0035091\~phosphoinositide binding                                                            5       0.025094   29.45
  GOTERM_MF_FAT          GO:0016208\~AMP binding                                                                         3       0.028747   33.00
  GOTERM_MF_FAT          GO:0003779\~actin binding                                                                       9       0.028844   33.09

###### 

KEGG pathways enriched by co-expression genes of homeobox A3 (HOXA3) mRNA in non-small cell lung cancer.

  Category       Term                                              Count   P-value   FDR
  -------------- ------------------------------------------------- ------- --------- -------
  KEGG_PATHWAY   hsa04510:Focal adhesion                           12      0.001     0.76
  KEGG_PATHWAY   hsa05200:Pathways in cancer                       15      0.001     1.67
  KEGG_PATHWAY   hsa04350:TGF-beta signaling pathway               7       0.004     4.34
  KEGG_PATHWAY   hsa04540:Gap junction                             7       0.004     4.84
  KEGG_PATHWAY   hsa04010:MAPK signaling pathway                   12      0.006     7.01
  KEGG_PATHWAY   hsa05218:Melanoma                                 6       0.008     8.33
  KEGG_PATHWAY   hsa05212:Pancreatic cancer                        6       0.008     8.81
  KEGG_PATHWAY   hsa05220:Chronic myeloid leukemia                 6       0.010     10.36
  KEGG_PATHWAY   hsa05222:Small cell lung cancer                   6       0.015     15.93
  KEGG_PATHWAY   hsa05210:Colorectal cancer                        6       0.015     15.93
  KEGG_PATHWAY   hsa04512:ECM-receptor interaction                 6       0.015     15.93
  KEGG_PATHWAY   hsa05215:Prostate cancer                          6       0.019     19.63
  KEGG_PATHWAY   hsa04912:GnRH signaling pathway                   6       0.028     27.23
  KEGG_PATHWAY   hsa04916:Melanogenesis                            6       0.029     28.15
  KEGG_PATHWAY   hsa04060:Cytokine-cytokine receptor interaction   10      0.039     35.71

###### 

The top 10 most significant items of Gene Ontology (GO) terms of the co-expression genes of homeobox A3 (HOXA3) mRNA in lung adenocarcinoma.

  Category               Term                                                                                            Count   P-value    FDR
  ---------------------- ----------------------------------------------------------------------------------------------- ------- ---------- -----------
  Biological Processes                                                                                                                      
  GOTERM_BP_FAT          GO:0048706\~embryonic skeletal system development                                               8       3.41E-05   0.056837
  GOTERM_BP_FAT          GO:0001501\~skeletal system development                                                         14      1.07E-04   0.178201
  GOTERM_BP_FAT          GO:0045682\~regulation of epidermis development                                                 5       1.17E-04   0.194494
  GOTERM_BP_FAT          GO:0030334\~regulation of cell migration                                                        10      1.80E-04   0.299680
  GOTERM_BP_FAT          GO:0042981\~regulation of apoptosis                                                             23      1.97E-04   0.328453
  GOTERM_BP_FAT          GO:0043067\~regulation of programmed cell death                                                 23      2.27E-04   0.377505
  GOTERM_BP_FAT          GO:0010941\~regulation of cell death                                                            23      2.39E-04   0.397502
  GOTERM_BP_FAT          GO:0048705\~skeletal system morphogenesis                                                       8       3.64E-04   0.604848
  GOTERM_BP_FAT          GO:0040012\~regulation of locomotion                                                            10      4.64E-04   0.770756
  GOTERM_BP_FAT          GO:0051270\~regulation of cell motion                                                           10      4.81E-04   0.798787
  Cellular ψomponents                                                                                                                       
  GOTERM_CC_FAT          GO:0005626\~insoluble fraction                                                                  22      0.000184   0.237025
  GOTERM_CC_FAT          GO:0005624\~membrane fraction                                                                   20      0.000837   1.072817
  GOTERM_CC_FAT          GO:0031012\~extracellular matrix                                                                12      0.001071   1.370868
  GOTERM_CC_FAT          GO:0044420\~extracellular matrix part                                                           7       0.001490   1.902184
  GOTERM_CC_FAT          GO:0045177\~apical part of cell                                                                 8       0.002892   3.662636
  GOTERM_CC_FAT          GO:0000267\~cell fraction                                                                       22      0.004675   5.857488
  GOTERM_CC_FAT          GO:0042995\~cell projection                                                                     16      0.006747   8.351548
  GOTERM_CC_FAT          GO:0005578\~proteinaceous extracellular matrix                                                  10      0.006859   8.483923
  GOTERM_CC_FAT          GO:0016324\~apical plasma membrane                                                              6       0.013372   15.921503
  GOTERM_CC_FAT          GO:0016323\~basolateral plasma membrane                                                         7       0.020688   23.607821
  Molecular ϕunctional                                                                                                                      
  GOTERM_MF_FAT          GO:0043565\~sequence-specific DNA binding                                                       20      0.000041   0.056109
  GOTERM_MF_FAT          GO:0008047\~enzyme activator activity                                                           11      0.004149   5.548392
  GOTERM_MF_FAT          GO:0005547\~phosphatidylinositol-3,4,5-trisphosphate binding                                    3       0.004179   5.587211
  GOTERM_MF_FAT          GO:0016641\~oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor   3       0.010187   13.113973
  GOTERM_MF_FAT          GO:0030695\~GTPase regulator activity                                                           11      0.014540   18.214548
  GOTERM_MF_FAT          GO:0016638\~oxidoreductase activity, acting on the CH-NH2 group of donors                       3       0.016640   20.575093
  GOTERM_MF_FAT          GO:0060589\~nucleoside-triphosphatase regulator activity                                        11      0.016712   20.655661
  GOTERM_MF_FAT          GO:0035091\~phosphoinositide binding                                                            5       0.025094   29.453780
  GOTERM_MF_FAT          GO:0016208\~AMP binding                                                                         3       0.028747   32.997529
  GOTERM_MF_FAT          GO:0003779\~actin binding                                                                       9       0.028844   33.089357

###### 

KEGG pathway enriched by co-expression genes of homeobox A3 (HOXA3) mRNA in lung adenocarcinoma.

  Category       Term                                  Count   P-value    FDR
  -------------- ------------------------------------- ------- ---------- -----------
  KEGG_PATHWAY   hsa04510:Focal adhesion               12      3.84E-05   0.042706
  KEGG_PATHWAY   hsa04512:ECM-receptor interaction     6       0.004145   4.514261
  KEGG_PATHWAY   hsa05218:Melanoma                     5       0.012451   13.009202
  KEGG_PATHWAY   hsa05212:Pancreatic cancer            5       0.013063   13.603250
  KEGG_PATHWAY   hsa05210:Colorectal cancer            5       0.021874   21.802852
  KEGG_PATHWAY   hsa05222:Small cell lung cancer       5       0.021874   21.802852
  KEGG_PATHWAY   hsa05200:Pathways in cancer           10      0.022490   22.349251
  KEGG_PATHWAY   hsa05215:Prostate cancer              5       0.026406   25.738703
  KEGG_PATHWAY   hsa05223:Non-small cell lung cancer   4       0.031134   29.652037
  KEGG_PATHWAY   hsa05214:Glioma                       4       0.045993   40.760927
  KEGG_PATHWAY   hsa04010:MAPK signaling pathway       8       0.052597   45.164053
  KEGG_PATHWAY   hsa05220:Chronic myeloid leukemia     4       0.070302   55.541161
  KEGG_PATHWAY   hsa04144:Endocytosis                  6       0.084942   62.734617
  KEGG_PATHWAY   hsa04350:TGF-beta signaling pathway   4       0.099275   68.735075
  KEGG_PATHWAY   hsa04012:ErbB signaling pathway       4       0.099275   68.735075

###### 

Top 10 with combined co-expression score that the protein-protein interaction (PPI) of homeobox A3 (HOXA3) co-expression genes in non-small cell lung cancer.

  \#Node1   Node2    Node1 STRING internal ID   Homology   Co-expression   Experimentally determined interaction   Automated text mining   Combined score
  --------- -------- -------------------------- ---------- --------------- --------------------------------------- ----------------------- ----------------
  STX2      SNAP25   1858001                    0          0.093           0.939                                   0.905                   0.998
  CDKN2B    CDK6     1846519                    0          0.054           0.432                                   0.763                   0.985
  DUSP10    MAPK1    1854467                    0          0.053           0.498                                   0.705                   0.984
  CALD1     MYLK     1854225                    0          0.248           0                                       0.791                   0.982
  MITF      MAPK1    1847592                    0          0.048           0.395                                   0.733                   0.982
  ARRB1     MAPK1    1860799                    0          0               0.43                                    0.658                   0.978
  ITSN1     ITSN2    1857363                    0.965      0               0.702                                   0.726                   0.969
  EGFR      MAPK1    1846445                    0.632      0               0.503                                   0.932                   0.965
  MALT1     CARD10   1850132                    0          0               0.115                                   0.63                    0.964
  RUNX2     MAPK1    1855482                    0          0               0                                       0.639                   0.962

###### 

Top 10 with combined co-expression score that the protein-protein interaction (PPI) of homeobox A3 (HOXA3) co-expression gene intersection in non-small cell lung cancer enriched in significant signalling pathways.

  \#Node1   Node2    Node1 STRING internal ID   Homology   Co-expression   Experimentally determined interaction   Automated text mining   Combined score
  --------- -------- -------------------------- ---------- --------------- --------------------------------------- ----------------------- ----------------
  EGFR      MAPK1    1846445                    0.632      0               0.503                                   0.932                   0.965
  COL6A1    COL1A1   1854318                    0.617      0.504           0                                       0.49                    0.957
  MYLK      MAPK1    1853981                    0.636      0               0                                       0.711                   0.925
  LAMA3     LAMA4    1850649                    0.804      0               0                                       0.115                   0.901
  PDGFD     EGFR     1858075                    0          0               0                                       0.49                    0.893
  EGFR      TNC      1846445                    0          0               0.36                                    0.72                    0.813
  THBS1     COL1A1   1844779                    0          0.1             0.324                                   0.463                   0.645
  TNC       MAPK1    1845696                    0          0               0                                       0.576                   0.576
  TNC       THBS1    1845696                    0          0.052           0                                       0.533                   0.538
  FLNC      MAPK1    1850897                    0          0               0.066                                   0.475                   0.49
  EGFR      MAPK1    1846445                    0.632      0               0.503                                   0.932                   0.965
  COL6A1    COL1A1   1854318                    0.617      0.504           0                                       0.49                    0.957
  MYLK      MAPK1    1853981                    0.636      0               0                                       0.711                   0.925
  LAMA3     LAMA4    1850649                    0.804      0               0                                       0.115                   0.901
  PDGFD     EGFR     1858075                    0          0               0                                       0.49                    0.893

###### 

Top 10 with combined score co-expression correlation by STRING 10.5 of homeobox A3 (HOXA3) co-expression genes in lung adenocarcinoma.

  \#Node1   Node2    Node1 STRING internal ID   Homology   Co-expression   Experimentally determined interaction   Automated text mining   Combined score
  --------- -------- -------------------------- ---------- --------------- --------------------------------------- ----------------------- ----------------
  STX2      SNAP25   1858001                    0          0.093           0.939                                   0.905                   0.998
  ARRB1     MAPK1    1860799                    0          0               0.43                                    0.658                   0.978
  EGFR      MAPK1    1846445                    0.632      0               0.503                                   0.932                   0.965
  MALT1     CARD10   1850132                    0          0               0.115                                   0.63                    0.964
  COL6A1    COL1A1   1854318                    0.617      0.504           0                                       0.49                    0.957
  PDE10A    ADCY6    1862089                    0          0.207           0.169                                   0.384                   0.954
  ARRB1     EGFR     1860799                    0          0               0.165                                   0.416                   0.947
  EGFR      CFTR     1846445                    0          0               0                                       0.445                   0.942
  EGFR      ERBB3    1846445                    0.921      0.05            0.36                                    0.956                   0.938
  TGFB2     THBS1    1854475                    0          0.046           0                                       0.364                   0.934
  STX2      SNAP25   1858001                    0          0.093           0.939                                   0.905                   0.998
  ARRB1     MAPK1    1860799                    0          0               0.43                                    0.658                   0.978
  EGFR      MAPK1    1846445                    0.632      0               0.503                                   0.932                   0.965
  MALT1     CARD10   1850132                    0          0               0.115                                   0.63                    0.964
  COL6A1    COL1A1   1854318                    0.617      0.504           0                                       0.49                    0.957

###### 

Top 10 with combined co-expression score that the protein-protein interaction (PPI) of homeobox A3 (HOXA3) co-expression gene intersection in lung adenocarcinoma enriched in significant signalling pathways.

  \#Node1   Node2    Node1 STRING internal ID   Homology   Co-expression   Experimentally determined interaction   Automated text mining   Combined score
  --------- -------- -------------------------- ---------- --------------- --------------------------------------- ----------------------- ----------------
  EGFR      MAPK1    1846445                    0.632      0               0.503                                   0.932                   0.965
  COL6A1    COL1A1   1854318                    0.617      0.504           0                                       0.49                    0.957
  MYLK      MAPK1    1853981                    0.636      0               0                                       0.711                   0.925
  LAMA3     LAMA4    1850649                    0.804      0               0                                       0.115                   0.901
  PDGFD     EGFR     1858075                    0          0               0                                       0.49                    0.893
  EGFR      TNC      1846445                    0          0               0.36                                    0.72                    0.813
  THBS1     COL1A1   1844779                    0          0.1             0.324                                   0.463                   0.645
  TNC       MAPK1    1845696                    0          0               0                                       0.576                   0.576
  TNC       THBS1    1845696                    0          0.052           0                                       0.533                   0.538
  FLNC      MAPK1    1850897                    0          0               0.066                                   0.475                   0.49
  AKT3      MAPK1    1845421                    0.65       0.134           0.292                                   0.576                   0.486
  EGFR      THBS1    1846445                    0          0               0                                       0.457                   0.457
  COL6A1    TNC      1854318                    0          0.055           0                                       0.424                   0.432
  TNC       COL1A1   1845696                    0          0.1             0                                       0.369                   0.408
  EGFR      MAPK1    1846445                    0.632      0               0.503                                   0.932                   0.965

[^1]: Contributed equally
